News

Astra Zeneca ends AZD2820 study
Enlarge image

BusinessSwedenUK

Astra Zeneca ends AZD2820 study

11.09.2012 - Swedish-British pharma Astra Zeneca has stopped the development of one obesity drug but promises to back partner Palatin with the other candidates.

US company Palatin Technologies, Inc. (Cranbury) experienced a setback for one of its developed drugs in June this year when its partner AstraZeneca PLC from Europe paused a Phase I clinical trial after a serious adverse event. Now, the Swedish-British pharma giant decided, after a thorough review, to end the development of this drug completely. However, Palatin also announced that AstraZeneca remains committed to the collaboration programme at large to discover, develop and commercialise compounds that target melanocortin-4 receptors for the treatment of obesity, diabetes and related metabolic syndrome.

The ditched clinical candidate called AZD2820 is a subcutaneously-administered peptide that partially agonises the melanocortin-4 receptor. Phase I clinical trials as a single-agent therapy for the treatment of obesity started in the first half of 2011 after AstraZeneca had selected the drug from the collaborative research programme with Palatin Technologies. The single centre study was expected to enrol 90 subjects with a body mass index between 30 and 35 in a randomised, single-blind, placebo-controlled, Phase I trial in healthy male volunteers. After 11 subjects had completed their dosing regimen, the trial was halted by the Safety Review Committee because it suspected that one subject may have had an allergic reaction following his first dose. The volunteer fully recovered but the review by AstraZeneca said that it cannot be excluded that the adverse reactiom was linked to AZD2820. The company however also stated, that it is unlikely that this event was related to melanocortin receptor activation as a mode of action.

http://www.european-biotechnology-news.com/news/news/2012-03/astra-zeneca-ends-azd2820-study.html

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.36 CHF5.88%
  • MERCK KGAA94.27 EUR2.25%
  • STRATEC BIOMEDICAL46.09 EUR1.97%

FLOP

  • VITA 345.55 EUR-3.48%
  • EVOTEC3.75 EUR-2.60%
  • MOLOGEN5.26 EUR-2.59%

TOP

  • WILEX3.15 EUR57.5%
  • THERAMETRICS0.07 CHF16.7%
  • BASILEA120.00 CHF15.2%

FLOP

  • SANTHERA96.30 CHF-16.6%
  • 4SC0.78 EUR-14.3%
  • MOLOGEN5.26 EUR-13.2%

TOP

  • SANTHERA96.30 CHF2434.2%
  • WILEX3.15 EUR433.9%
  • FORMYCON16.23 EUR100.9%

FLOP

  • CYTOS0.36 CHF-87.8%
  • MOLOGEN5.26 EUR-56.7%
  • BIOFRONTERA1.92 EUR-51.3%

No liability assumed, Date: 02.03.2015